Old Web
English
Sign In
Acemap
>
authorDetail
>
Michael-Friedrich Boettcher
Michael-Friedrich Boettcher
Bayer HealthCare Pharmaceuticals
Medicine
Very low-density lipoprotein
Torcetrapib
Cholesterylester transfer protein
Pharmacodynamics
2
Papers
22
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
How safe are our studies? Analysis of adverse events in Bayer First-in-Human trials from 2006 to 2016
2019
CP | Principles and Practice of Constraint Programming
David Jung
Michael-Friedrich Boettcher
Georg Wensing
Show All
Source
Cite
Save
Citations (1)
Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60–5521, a potent inhibitor of cholesteryl ester transfer protein
2012
British Journal of Clinical Pharmacology
Michael-Friedrich Boettcher
Roland Heinig
Carsten Schmeck
Christian Kohlsdorfer
Matthias Ludwig
Anja Schaefer
Sabine Gelfert-Peukert
Georg Wensing
Olaf Weber
Show All
Source
Cite
Save
Citations (21)
1